<DOC>
	<DOCNO>NCT02662114</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate effectiveness Tresiba® ( insulin degludec ) switch basal insulin population type 1 type 2 diabetes mellitus . EU-TREAT ( EUropean TREsiba AudiT )</brief_summary>
	<brief_title>Investigating Effectiveness Tresiba® ( Insulin Degludec ) After Switching Basal Insulin Population With Type 1 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . Studyrelated activity data collection medical record patient Age least 18 year time Tresiba® initiation T1DM insulintreated T2DM patient Switched Tresiba® ( without prandial insulin ) basal insulin ( without prandial insulin ) . Switch must occur least 6 month prior data collection patient may may treat Tresiba® time patient selection Previously treat basal insulin ( without prandial insulin ) least 6 month prior switch Tresiba® At least one document medical visit first 9 month Tresiba® initiation Minimum available data time Tresiba® initiation : age , type diabetes , HbA1c ( Glycated haemoglobin ) , duration diabetes , duration type insulin treatment , medical followup study site least 1 year , eGFR ( Estimated glomerular filtration rate ) value last 12 month Previous participation study . Participation define sign Informed Consent Participation diabetes clinical trial receipt investigational medicinal product 12 month time initiation Tresiba® Current participation another noninterventional study insulin degludec ( Tresiba® ) Patients treat continuous subcutaneous insulin infusion premix insulin 6 month prior receive Tresiba®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>